Skip to Content

Stryker Corp SYK

Rating as of

Morningstar’s Analysis

Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price


5-Star Price


Economic Moat


Capital Allocation


As Democrats Near Control of Senate, We Don't Expect Major Changes for Device Industry

Julie Utterback, CFA Senior Equity Analyst

Analyst Note

| Julie Utterback, CFA |

In a surprise twist to the election season, the Democrats are very close to winning the remaining two U.S. Senate seats in the Georgia runoffs. If the elections go to the Democrats, we suspect Joe Biden's administration will seek to implement further healthcare reforms. However, with such a slim majority in the Senate, compromises on ideals espoused by the Biden campaign may be required to get healthcare legislation passed with support from moderate Democrats. With significant compromises possible in the next several months as the legislation is crafted, we will keep steady on our moat and valuation views until more clarity emerges on the potential changes to the healthcare industry.

Read Full Analysis

Company Profile

Business Description

Stryker designs, manufactures, and markets an array of medical equipment, instruments, consumable supplies, and implantable devices. The product portfolio includes hip and knee replacements, endoscopy systems, operating room equipment, embolic coils, and spinal devices. Stryker remains one of the three largest competitors in reconstructive orthopedic implants and holds the leadership position in operating room equipment. Slightly more than a quarter of Stryker's total revenue currently comes from outside the United States.

2825 Airview Boulevard
Kalamazoo, MI, 49002
T +1 269 385-2600
Sector Healthcare
Industry Medical Devices
Most Recent Earnings Sep 30, 2020
Fiscal Year End Dec 31, 2019
Stock Type Classic Growth
Employees 40,000